Evaluating intermittent androgen-deprivation therapy phase III clinical trials: The devil is in the details

Maha Hussain*, Catherine Tangen, Celestia Higano, Nicholas Vogelzang, Ian Thompson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Fingerprint

Dive into the research topics of 'Evaluating intermittent androgen-deprivation therapy phase III clinical trials: The devil is in the details'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science